[CROI 2018] PROGRAMMA & VARIE
[CROI 2018] PROGRAMMA & VARIE
Boston, 4-7 marzo, CROI 2018.
Fra due settimane inizia il CROI. Il programma completo sarà online non tanto prima del congresso e solo quando sarà disponibile potrò elencare le presentazioni che seguirò e di cui cercherò di scrivere qualcosa nel forum.
Dalla Preliminary Agenda si vede che, oltre a parlare ancora di co-infezione con HCV, per il secondo anno di seguito, questo è l'anno della tubercolosi, che verrà affrontata in diverse sessioni e in decine di presentazioni. Si parlerà anche molto di bambini, di infezione pediatrica, di adolescenti, di trattamenti, di allattamento - io di questo non scriverò nulla, credo.
Di seguito, in verde, le sessioni che seguirò per prime.
Quando avrò le idee più chiare sul programma o arriveranno notizie interessanti, aggiornerò il thread.
Re: [CROI 2018] PROGRAMMA & VARIE
Grazie Dora!
In generale qual è la tua aspettativa quest’anno?
In generale qual è la tua aspettativa quest’anno?
Una pianificazione attenta non sostituirà mai una bella botta di culo!
Re: [CROI 2018] PROGRAMMA & VARIE
Per adesso di aspettative non ne ho, perché questo programma preliminare è così stringato che mancano perfino i titoli delle sessioni delle presentazioni orali, quindi non ho idea neppure di quali saranno gli argomenti.Gabriel81 ha scritto:In generale qual è la tua aspettativa quest’anno?
Ne riparliamo quando pubblicano il programma definitivo - con i titoli degli abstract, credo che riusciremo almeno a capire dove vanno a parare (salvo sviste clamorose da parte mia ).
Re: [CROI 2018] PROGRAMMA & VARIE
Molto interessante la sessione "Stop it now".
Credo che una cura, anche solo funzionale, si potrà trovare grazie agli studi dei meccanismi dei CD8 nei pazieti trattai precocemente!
Speriamo!!!
Credo che una cura, anche solo funzionale, si potrà trovare grazie agli studi dei meccanismi dei CD8 nei pazieti trattai precocemente!
Speriamo!!!
Re: [CROI 2018] PROGRAMMA & VARIE
L'HIV & LE DONNE
Quest'anno molto spazio al CROI 2018 sarà dedicato alle donne - e le ragioni sono ovvie, dal momento non solo che le donne con HIV presentano sovente caratteristiche diverse da quelle degli uomini e affrontano esperienze diverse come la gravidanza, l'allattamento e la menopausa, ma anche che in molti Paesi, soprattutto le donne delle fasce d'età più giovani, sono colpite dall'infezione in modo assolutamente sproporzionato; sarà anche il momento, durante il simposio "Martin Delaney Presentation on Women in Research: Science is Better When Women Are Represented", per parlare di donne nella ricerca (per qualche riferimento: le *letture per il weekend* del 16 febbraio scorso).
Avremo dunque al CROI sessioni dedicate alla PrEP, al ruolo del microbiota vaginale nel rischio di HIV/MST nelle adolescenti, alle questioni dell'allattamento con un'intera sessione dedicata - "Breast Is Best, but It's a Viral Milkshake!".
Subito prima dell'inizio del congresso, inoltre, si terrà l'8° International Workshop on HIV & Women | 2-3 March 2018 | Boston, MA, USA, che vede un programma molto intenso, con discussioni sulla PrEP, sulle adolescenti, sulle linee guida da seguirsi in gravidanza e allattamento, sulle donne e le droghe, sulla ricerca relativa a HIV e donne.
Antonella d'Arminio Monforte, che è senz'altro una fra le ricercatrici italiane più attente alle questioni femminili, è membro del Comitato Scientifico del workshop.
Re: [CROI 2018] PROGRAMMA & VARIE
È online il programma completo del CROI
[cliccare sull'immagine] Segnalo in particolare le sessioni
Nei prossimi giorni, guarderò i poster.
[cliccare sull'immagine] Segnalo in particolare le sessioni
- - Oral Abstract O-02 ART: NEW DATA AND NEW INSIGHTS (#22 SWITCH TO BICTEGRAVIR/F/TAF FROM DTG AND ABC/3TC; #23 IMPACT OF RALTEGRAVIR INTENSIFICATION OF FIRST-LINE ART ON IRIS IN THE REALITY TRIAL; #26 MULTIPLE DAILY DOSES OF MK-8591 AS LOW AS 0.25 MG ARE EXPECTED TO SUPPRESS HIV)
- Symposium S-1 STOP IT NOW: TARGETING EARLY INFECTION EVENTS (#48 - 51)
- Oral Abstract O-05 THE HIV RESERVOIR AND VIRAL REPLICATION (#66 - 73LB, dolutegravir ↑, romidepsina ↓, PGT121+GS9620 ↑↑ in macachi)
- Oral Abstract O-06 NON-AIDS COMPLICATIONS (#74 - 81LB)
- Oral Abstract O-07 OF MICE, MONKEYS, AND MEN: PrEP FROM PRECLINICAL TO POPULATION LEVEL IMPACT (#82 - 89LB)
- Themed Discussion TD-06 ROLE OF THE MICROBIOME IN HIV INFECTION (AND VICE-VERSA) (#271 - 275, in particolare #274 EFFECTS OF PROBIOTIC VISBIOME ES ON COLONIC MUCOSAL CD4 CELLS: RESULTS FROM A5352S)
- Themed Discussion TD-07 AGING BRAIN AND HIV: BEFORE AND AFTER (#437 - 440 + 425)
- Themed Discussion TD-08 ARE INTEGRASE STRAND-TRANSFER INHIBITORS RESISTANCE PROOF? (#542 - 546)
- Themed Discussion TD-09 BONES OF CONTENTION (#720 - 724)
- Symposium S-6 LIFE EXPECTANCY AT 25 (#102 - 104)
- Symposium S-7 PrEP WORKS, NOW WHAT? (#105 - 108)
- Oral Abstract O-09 HIV REPLICATION, INHIBITION, AND RESTRICTION (#113LB TRISPECIFIC ANTIBODIES FOR PREVENTION AND TREATMENT OF HIV-1 INFECTION)
- Oral Abstract O-10 THE CNS RESERVOIR(S), REBOUND, AND BRAIN INJURY (#119 - 126)
- Themed Discussion TD-12 T AND B CELL INTERACTIONS IN LYMPH NODES (#284 - 287)
- Oral Abstract O-14 DEFINING THE HIV RESERVOIR (#151 - 158, dove si ribadisce la debacle del CD32 vista a dicembre a Miami, ma in compenso non mi pare arrivino nuove botte in testa da parte di Siliciano e allievi)
- Symposium S-8 ART: THE NEXT 25 YEARS (#159 INTEGRATING NEW ANTIRETROVIRAL THERAPIES; #160 BROADLY NEUTRALIZING ANTIBODIES FOR HIV PREVENTION AND TREATMENT: DREAM OR PIPE DREAM?)
Nei prossimi giorni, guarderò i poster.
Re: [CROI 2018] PROGRAMMA & VARIE
Elenco qui alcune delle sessioni e alcuni titoli di poster che conto di vedere quando saranno online. Sono solo degli appunti per me, senza nessuna pretesa di completezza.
Poster P-A1 MOLECULAR VIROLOGY
173 PROGRESS IN DEVELOPING HIGHLY POTENT SECOND GENERATION MATURATION INHIBITORS
Poster P-B1 HIV TRANSMISSION AND DISEASE PROGRESSION
208 DETERMINANTS OF SUBOPTIMAL IMMUNOLOGICAL RESPONSE AFTER ART INITIATION IN ACUTE HIV
209 CD4 INCREASE <100 CELLS/MM3 DURING 2 YEARS OF ART IS ASSOCIATED WITH WORSE OUTCOMES
215 CD4 T CELL DEPLETION IN PRIMATES IS ASSOCIATED WITH LOSS OF INNATE LYMPHOID CELLS
Poster P-C3 NEUTRALIZING ANTIBODIES
289 BROAD SPECTRUM OF NEUTRALIZATION-ENHANCEMENT BY NOVEL CD4MIMIC COMPOUND YIR-821
Poster P-C4 NON-NEUTRALIZING ANTIBODIES
Poster P-D01 MECHANISMS OF HIV LATENCY AND ITS REVERSAL
322 TRANSCRIPTIONAL REPROGRAMMING IN CCR5+ MEMORY CD4+ T CELLS PROMOTES HIV-1 LATENCY
324 SYNTHETIC INGENOLS MAXIMIZE PROTEIN KINASE C-INDUCED HIV-1 LATENCY REVERSAL
325 EXOSOMAL TAT REACTIVATES LATENT HIV-1
328 IDENTIFICATION OF SMALL MOLECULES THAT INHIBIT REACTIVATION OF LATENT HIV-1
Poster P-D02 INSIGHTS FROM HIV REBOUND
334 IMPACT OF TREATMENT INTERRUPTION ON HIV RESERVOIRS AND IMMUNOLOGIC PARAMETERS
335 SHORT-TERM ART INTERRUPTION HAS LITTLE EFFECT ON LEVELS OF INTEGRATED PROVIRAL DNA
336 HIV REBOUND DRIVEN BY RARE SUPERSPREADING CD4+ T CELL LINEAGES
338 A5340: BRIEF ATI DOES NOT ALTER THE SIZE OR COMPOSITION OF THE LATENT HIV-1 RESERVOIR
Poster P-D03 HIV RESERVOIRS IN ACUTE INFECTION
339 HIV RESERVOIR ESTABLISHMENT DURING HYPERACUTE CLADE C INFECTION
341 HIV RNA PERSISTS LONG-TERM IN LYMPH NODES OF INDIVIDUALS INITIATED ON ART IN FIEBIG I
342 THE HIV RESERVOIR DURING EARLY ANTIRETROVIRAL THERAPY AND MARAVIROC INTENSIFICATION
343 HIV SEROLOGY FOLLOWING TREATMENT INTERRUPTION IN VERY EARLY TREATED PEOPLE
Poster P-D04 IMPACT OF ANTIRETROVIRAL THERAPY ON HIV/SIV RESERVOIRS
**344 REEVALUATING SIGNALS OF VIRAL REPLICATION & EVOLUTION IN LYMPHOID TISSUE DURING ART
346 SPREAD OF HIV-DNA IN CD4+ T-CELL SUBSETS DEPENDS ON ART INITIATION TIMING
347 RAPID DECAY OF HIV PERSISTENCE MARKERS IN ACUTELY ART-TREATED INDIVIDUALS IN PERU
Poster P-E2 NEUROPSYCHOLOGIC COMPLICATIONS OF HIV INFECTION
*419 BENEFICIAL EFFECT OF 6 MONTHS OF PROBIOTICS ON ASYMPTOMATIC NEUROCOGNITIVE IMPAIRMENT
Poster P-H1 ANTIRETROVIRAL TREATMENT-NAIVE STUDIES
Poster P-H2 INTEGRASE STRAND-TRANSFER INHIBITORS: SAFETY, EFFICACY, AND IRIS
Poster P-H3 ANTIRETROVIRAL SWITCH STUDIES
Poster P-L1 HIV-ASSOCIATED CANCER: EPIDEMIOLOGY AND OUTCOMES
651 STILL HIGH RISK OF VIRUS-RELATED CANCER DESPITE 20 YEARS OF cART IN ICONA COHORT
656LB INTERIM SAFETY ANALYSIS OF CITN-12: PEMBROLIZUMAB IN PATIENTS WITH HIV AND CANCER
Poster P-M7 DISLIPIDEMIA: MECHANISMS AND INTERVENTIONS
Poster P-O1 TUBERCULOSIS INCIDENCE, SCREENING, AND DIAGNOSIS
768 HIV-ASSOCIATED TB IN A LOW BURDEN COUNTRY: IS SCREENING FOR LATENT TB STILL NEEDED?
Poster P-B2 IMMUNE ACTIVATION AND SUPPRESSION IN HIV INFECTION
Poster P-B3 NATURAL AND UNNATURAL CONTROL OF HIV INFECTION
Poster P-B4 CELL AND TISSUE DISREGULATION IN HIV INFECTION
Poster P-B5 COMPARTMENTS FOR HIV REPLICATION
Poster P-C5 VACCINE DESIGN AND TESTING
309 SIV REBOUND KINETICS FOLLOWING TLR7-AGONIST & THERAPEUTIC VACCINE ADMINISTRATION
310 IPROTECT1: A VAC-3S VACCINE PHASE II STUDY IN HIV-INFECTED PATIENTS
311 PHASE I CLINICAL TRIAL OF AN MRNA-BASED THERAPEUTIC VACCINE AGAINST HIV-1 INFECTION
Poster P-C6 NOVEL INTERVENTIONAL STRATEGIES
313 RIFAXIMIN USE DOES NOT ALTER SCD14 LEVELS IN HIV INFECTED PERSONS ON SUPPRESSIVE ART
314 EFFECT OF SWITCHING TO RALTEGRAVIR AND/OR ADDING LOSARTAN ON HIV IMMUNE ACTIVATION
315 TLR9 AGONIST ENHANCES B CELL DIFFERENTIATION AND ANTIBODY PRODUCTION IN HIV+ ADULTS
316 A BISPECIFIC APPROACH FOR TARGETING NEGATIVE CHECKPOINT RECEPTORS IN HIV-1 LATENCY
318 ALTERED AND INCOMPLETE IMMUNE RECONSTITUTION IN HIV+ STEM CELL TRANSPLANT RECIPIENTS
**319LB Α4Β7-BLOCKADE COMBINED WITH VRC01 MODULATES IMMUNE RESPONSES TO SHIV-AD8 INFECTION
Poster P-D05 INTERVENTIONS IN SIV MODELS OF PERSISTENCE
**348 IL-21 PLUS IFN-Α LIMITS VIRAL PERSISTENCE AND REBOUND IN SIV-INFECTED RHESUS MACAQUES
349 CD4 DEPLETION IN SIV-INFECTED MACAQUES ON EARLY ART HAS NO IMPACT ON VIRAL REBOUND
350 SIV PERSISTS IN LYMPHOID TISSUES DESPITE ALEMTUZUMAB INDUCED CD4+ T CELL DEPLETION
351 ΔCCR5 ANTI-HIV CAR T CELLS ENGRAFT AND PERSIST IN SHIV INFECTED PIGTAIL MACAQUES
**353LB IL-15 TREATMENT INCREASES CYTOTOXIC LYMPHOCYTES IN LN FOLLICLES AND REDUCES SHIV RNA
Poster P-D06 NOVEL INTERVENTIONS TO TARGET HIV RESERVOIRS
**356 A PHASE 1 STUDY OF ALT-803 (IL-15 SUPERAGONIST) TO CLEAR LATENT HIV RESERVOIRS
**357 EFFECT OF 24 WEEKS TLR9 AGONIST THERAPY ON CTL RESPONSES AND VIRAL REBOUND DURING ATI
358 IFN-Α INDUCES NK-DEPENDENT HIV DNA DECLINE IN ART-TREATED HIV/HCV COINFECTED PATIENTS
359 THE THERAPEUTIC VACCINE VACC-4X TARGETS GAG CTL EPITOPES WITH PREEXISTING MUTATIONS
Poster P-D07 CHARACTERIZING HIV RESERVOIRS
362 THE IMPACT OF ART DURATION ON THE INFECTION OF T CELLS WITHIN ANATOMIC SITES
363 PERSISTENCE OF CD4+PD-1HIGH T CELLS DESPITE LONG-TERM SUPPRESSIVE ART
364 PROVIRAL LANDSCAPE IN HIV-1 POST-TREATMENT CONTROLLERS AND NON-CONTROLLERS
365 HIV VIREMIA IS THE PRODUCT OF A SMALL FRACTION OF HIV INFECTED CELLS
367 PULMONARY MUCOSAL T CELLS AS POTENTIAL HIV RESERVOIRS DURING LONG-TERM ART
373 IDENTIFICATION OF MACROPHAGE RESERVOIRS THROUGH TROPISM OF HIV-1 ENVELOPES
374LB HEMATOPOIETIC STEM AND PROGENITOR CELLS ARE A UNIQUE FUNCTIONAL HIV RESERVOIR
Poster P-F4 ANTIRETROVIRAL PHARMACOLOGY IN COMPARTMENTS AND RESERVOIRS
Poster P-I1 TRANSMITTED DRUG RESISTANCE: A GLOBAL CONCERN
Poster P-I2 ANTIRETROVIRAL RESISTANCE AND RESPONSE TO INITIAL THERAPY
Poster P-I3 RESISTANCE ON ANTIRETROVIRAL THERAPY: THE PROBLEM PERSISTS!
Poster P-I4 ARE INTEGRASE STRAND-TRANSFER INHIBITORS RESISTANCE PROOF?
Poster P-N10 BIOMARKER PREDICTORS OF NON-AIDS EVENTS
763 NOVEL BIOMARKERS PREDICTIVE OF NON-AIDS EVENTS DURING ART-MEDIATED VIRAL SUPPRESSION
764 INFLAMMATION AND IMMUNE ACTIVATION MARKERS ASSOCIATED WITH NON-AIDS CANCERS IN HIV
765 SERUM ALBUMIN AS A LONG TERM PREDICTOR OF SERIOUS NON-AIDS EVENTS
Poster P-T09 PHASE I STUDIES OF MONOCLONAL ANTIBODIES IN NON-INFECTED ADULTS
1061 A PHASE I DOSE-ESCALATION STUDY OF MONOCLONAL ANTIBODY VRC07-523LS IN HEALTHY ADULTS
1062 A PHASE 1 TRIAL OF THE COMBINATION OF 3BNC117 AND 10-1074 IN HIV-UNINFECTED ADULTS
Poster P-A4 HIV AND HOST DEFENSES
Poster P-B6 THE MICROBIOME AND HIV: TRANSLOCATION AND INTERVENTION
Poster P-B7 EFFECTS OF HIV INFECTION ON THE MICROBIOME
Poster P-B8 ROLE OF THE MICROBIOME IN HIV INFECTION
Poster P-C1 KILLERS: NK AND CD8 CELLS
Poster P-C2 T AND B CELL INTERACTIONS IN LYMPH NODES
Poster P-D08 NOVEL INSIGHTS INTO HIV/SIV RESERVOIRS
**Poster P-D09 MARKERS OF HIV RESERVOIRS
Poster P-D10 QUANTIFYING HIV RESERVOIRS
Poster P-E5 CNS RESERVOIRS, ESCAPE, ANTIRETROVIRAL THERAPY, AND RESPONSES
**Poster P-F5 NOVEL FORMULATIONS FOR ANTIRETROVIRAL DRUG DELIVERY
Poster P-H4 ANTIRETROVIRAL TREATMENT EXPERIENCED STUDIES
Poster P-A1 MOLECULAR VIROLOGY
173 PROGRESS IN DEVELOPING HIGHLY POTENT SECOND GENERATION MATURATION INHIBITORS
Poster P-B1 HIV TRANSMISSION AND DISEASE PROGRESSION
208 DETERMINANTS OF SUBOPTIMAL IMMUNOLOGICAL RESPONSE AFTER ART INITIATION IN ACUTE HIV
209 CD4 INCREASE <100 CELLS/MM3 DURING 2 YEARS OF ART IS ASSOCIATED WITH WORSE OUTCOMES
215 CD4 T CELL DEPLETION IN PRIMATES IS ASSOCIATED WITH LOSS OF INNATE LYMPHOID CELLS
Poster P-C3 NEUTRALIZING ANTIBODIES
289 BROAD SPECTRUM OF NEUTRALIZATION-ENHANCEMENT BY NOVEL CD4MIMIC COMPOUND YIR-821
Poster P-C4 NON-NEUTRALIZING ANTIBODIES
Poster P-D01 MECHANISMS OF HIV LATENCY AND ITS REVERSAL
322 TRANSCRIPTIONAL REPROGRAMMING IN CCR5+ MEMORY CD4+ T CELLS PROMOTES HIV-1 LATENCY
324 SYNTHETIC INGENOLS MAXIMIZE PROTEIN KINASE C-INDUCED HIV-1 LATENCY REVERSAL
325 EXOSOMAL TAT REACTIVATES LATENT HIV-1
328 IDENTIFICATION OF SMALL MOLECULES THAT INHIBIT REACTIVATION OF LATENT HIV-1
Poster P-D02 INSIGHTS FROM HIV REBOUND
334 IMPACT OF TREATMENT INTERRUPTION ON HIV RESERVOIRS AND IMMUNOLOGIC PARAMETERS
335 SHORT-TERM ART INTERRUPTION HAS LITTLE EFFECT ON LEVELS OF INTEGRATED PROVIRAL DNA
336 HIV REBOUND DRIVEN BY RARE SUPERSPREADING CD4+ T CELL LINEAGES
338 A5340: BRIEF ATI DOES NOT ALTER THE SIZE OR COMPOSITION OF THE LATENT HIV-1 RESERVOIR
Poster P-D03 HIV RESERVOIRS IN ACUTE INFECTION
339 HIV RESERVOIR ESTABLISHMENT DURING HYPERACUTE CLADE C INFECTION
341 HIV RNA PERSISTS LONG-TERM IN LYMPH NODES OF INDIVIDUALS INITIATED ON ART IN FIEBIG I
342 THE HIV RESERVOIR DURING EARLY ANTIRETROVIRAL THERAPY AND MARAVIROC INTENSIFICATION
343 HIV SEROLOGY FOLLOWING TREATMENT INTERRUPTION IN VERY EARLY TREATED PEOPLE
Poster P-D04 IMPACT OF ANTIRETROVIRAL THERAPY ON HIV/SIV RESERVOIRS
**344 REEVALUATING SIGNALS OF VIRAL REPLICATION & EVOLUTION IN LYMPHOID TISSUE DURING ART
346 SPREAD OF HIV-DNA IN CD4+ T-CELL SUBSETS DEPENDS ON ART INITIATION TIMING
347 RAPID DECAY OF HIV PERSISTENCE MARKERS IN ACUTELY ART-TREATED INDIVIDUALS IN PERU
Poster P-E2 NEUROPSYCHOLOGIC COMPLICATIONS OF HIV INFECTION
*419 BENEFICIAL EFFECT OF 6 MONTHS OF PROBIOTICS ON ASYMPTOMATIC NEUROCOGNITIVE IMPAIRMENT
Poster P-H1 ANTIRETROVIRAL TREATMENT-NAIVE STUDIES
Poster P-H2 INTEGRASE STRAND-TRANSFER INHIBITORS: SAFETY, EFFICACY, AND IRIS
Poster P-H3 ANTIRETROVIRAL SWITCH STUDIES
Poster P-L1 HIV-ASSOCIATED CANCER: EPIDEMIOLOGY AND OUTCOMES
651 STILL HIGH RISK OF VIRUS-RELATED CANCER DESPITE 20 YEARS OF cART IN ICONA COHORT
656LB INTERIM SAFETY ANALYSIS OF CITN-12: PEMBROLIZUMAB IN PATIENTS WITH HIV AND CANCER
Poster P-M7 DISLIPIDEMIA: MECHANISMS AND INTERVENTIONS
Poster P-O1 TUBERCULOSIS INCIDENCE, SCREENING, AND DIAGNOSIS
768 HIV-ASSOCIATED TB IN A LOW BURDEN COUNTRY: IS SCREENING FOR LATENT TB STILL NEEDED?
Poster P-B2 IMMUNE ACTIVATION AND SUPPRESSION IN HIV INFECTION
Poster P-B3 NATURAL AND UNNATURAL CONTROL OF HIV INFECTION
Poster P-B4 CELL AND TISSUE DISREGULATION IN HIV INFECTION
Poster P-B5 COMPARTMENTS FOR HIV REPLICATION
Poster P-C5 VACCINE DESIGN AND TESTING
309 SIV REBOUND KINETICS FOLLOWING TLR7-AGONIST & THERAPEUTIC VACCINE ADMINISTRATION
310 IPROTECT1: A VAC-3S VACCINE PHASE II STUDY IN HIV-INFECTED PATIENTS
311 PHASE I CLINICAL TRIAL OF AN MRNA-BASED THERAPEUTIC VACCINE AGAINST HIV-1 INFECTION
Poster P-C6 NOVEL INTERVENTIONAL STRATEGIES
313 RIFAXIMIN USE DOES NOT ALTER SCD14 LEVELS IN HIV INFECTED PERSONS ON SUPPRESSIVE ART
314 EFFECT OF SWITCHING TO RALTEGRAVIR AND/OR ADDING LOSARTAN ON HIV IMMUNE ACTIVATION
315 TLR9 AGONIST ENHANCES B CELL DIFFERENTIATION AND ANTIBODY PRODUCTION IN HIV+ ADULTS
316 A BISPECIFIC APPROACH FOR TARGETING NEGATIVE CHECKPOINT RECEPTORS IN HIV-1 LATENCY
318 ALTERED AND INCOMPLETE IMMUNE RECONSTITUTION IN HIV+ STEM CELL TRANSPLANT RECIPIENTS
**319LB Α4Β7-BLOCKADE COMBINED WITH VRC01 MODULATES IMMUNE RESPONSES TO SHIV-AD8 INFECTION
Poster P-D05 INTERVENTIONS IN SIV MODELS OF PERSISTENCE
**348 IL-21 PLUS IFN-Α LIMITS VIRAL PERSISTENCE AND REBOUND IN SIV-INFECTED RHESUS MACAQUES
349 CD4 DEPLETION IN SIV-INFECTED MACAQUES ON EARLY ART HAS NO IMPACT ON VIRAL REBOUND
350 SIV PERSISTS IN LYMPHOID TISSUES DESPITE ALEMTUZUMAB INDUCED CD4+ T CELL DEPLETION
351 ΔCCR5 ANTI-HIV CAR T CELLS ENGRAFT AND PERSIST IN SHIV INFECTED PIGTAIL MACAQUES
**353LB IL-15 TREATMENT INCREASES CYTOTOXIC LYMPHOCYTES IN LN FOLLICLES AND REDUCES SHIV RNA
Poster P-D06 NOVEL INTERVENTIONS TO TARGET HIV RESERVOIRS
**356 A PHASE 1 STUDY OF ALT-803 (IL-15 SUPERAGONIST) TO CLEAR LATENT HIV RESERVOIRS
**357 EFFECT OF 24 WEEKS TLR9 AGONIST THERAPY ON CTL RESPONSES AND VIRAL REBOUND DURING ATI
358 IFN-Α INDUCES NK-DEPENDENT HIV DNA DECLINE IN ART-TREATED HIV/HCV COINFECTED PATIENTS
359 THE THERAPEUTIC VACCINE VACC-4X TARGETS GAG CTL EPITOPES WITH PREEXISTING MUTATIONS
Poster P-D07 CHARACTERIZING HIV RESERVOIRS
362 THE IMPACT OF ART DURATION ON THE INFECTION OF T CELLS WITHIN ANATOMIC SITES
363 PERSISTENCE OF CD4+PD-1HIGH T CELLS DESPITE LONG-TERM SUPPRESSIVE ART
364 PROVIRAL LANDSCAPE IN HIV-1 POST-TREATMENT CONTROLLERS AND NON-CONTROLLERS
365 HIV VIREMIA IS THE PRODUCT OF A SMALL FRACTION OF HIV INFECTED CELLS
367 PULMONARY MUCOSAL T CELLS AS POTENTIAL HIV RESERVOIRS DURING LONG-TERM ART
373 IDENTIFICATION OF MACROPHAGE RESERVOIRS THROUGH TROPISM OF HIV-1 ENVELOPES
374LB HEMATOPOIETIC STEM AND PROGENITOR CELLS ARE A UNIQUE FUNCTIONAL HIV RESERVOIR
Poster P-F4 ANTIRETROVIRAL PHARMACOLOGY IN COMPARTMENTS AND RESERVOIRS
Poster P-I1 TRANSMITTED DRUG RESISTANCE: A GLOBAL CONCERN
Poster P-I2 ANTIRETROVIRAL RESISTANCE AND RESPONSE TO INITIAL THERAPY
Poster P-I3 RESISTANCE ON ANTIRETROVIRAL THERAPY: THE PROBLEM PERSISTS!
Poster P-I4 ARE INTEGRASE STRAND-TRANSFER INHIBITORS RESISTANCE PROOF?
Poster P-N10 BIOMARKER PREDICTORS OF NON-AIDS EVENTS
763 NOVEL BIOMARKERS PREDICTIVE OF NON-AIDS EVENTS DURING ART-MEDIATED VIRAL SUPPRESSION
764 INFLAMMATION AND IMMUNE ACTIVATION MARKERS ASSOCIATED WITH NON-AIDS CANCERS IN HIV
765 SERUM ALBUMIN AS A LONG TERM PREDICTOR OF SERIOUS NON-AIDS EVENTS
Poster P-T09 PHASE I STUDIES OF MONOCLONAL ANTIBODIES IN NON-INFECTED ADULTS
1061 A PHASE I DOSE-ESCALATION STUDY OF MONOCLONAL ANTIBODY VRC07-523LS IN HEALTHY ADULTS
1062 A PHASE 1 TRIAL OF THE COMBINATION OF 3BNC117 AND 10-1074 IN HIV-UNINFECTED ADULTS
Poster P-A4 HIV AND HOST DEFENSES
Poster P-B6 THE MICROBIOME AND HIV: TRANSLOCATION AND INTERVENTION
Poster P-B7 EFFECTS OF HIV INFECTION ON THE MICROBIOME
Poster P-B8 ROLE OF THE MICROBIOME IN HIV INFECTION
Poster P-C1 KILLERS: NK AND CD8 CELLS
Poster P-C2 T AND B CELL INTERACTIONS IN LYMPH NODES
Poster P-D08 NOVEL INSIGHTS INTO HIV/SIV RESERVOIRS
**Poster P-D09 MARKERS OF HIV RESERVOIRS
Poster P-D10 QUANTIFYING HIV RESERVOIRS
Poster P-E5 CNS RESERVOIRS, ESCAPE, ANTIRETROVIRAL THERAPY, AND RESPONSES
**Poster P-F5 NOVEL FORMULATIONS FOR ANTIRETROVIRAL DRUG DELIVERY
Poster P-H4 ANTIRETROVIRAL TREATMENT EXPERIENCED STUDIES
Re: [CROI 2018] PROGRAMMA & VARIE
Molto interessanti le interviste che Filippo von Schloesser ha fatto ad alcuni scienziati italiani presenti a Boston: Massimo Andreaoni, Giovanni Di Perri e Massimo Galli.
Re: [CROI 2018] PROGRAMMA & VARIE
Sono disponibili i primi due Conference Reports for NATAP:
- - CROI 2018: Comorbidities and Inflammation, di David Shepp, Hofstra-Northwell, Manhasset
- Antiretroviral Therapy CROI 2018 New Agents/Combinations, di Joseph Eron, North Carolina at Chapel Hill